Acquisitions (Details) - USD ($) |
1 Months Ended | 12 Months Ended | ||
|---|---|---|---|---|
Oct. 11, 2022 |
Jun. 21, 2022 |
Dec. 31, 2022 |
Dec. 31, 2021 |
|
| Asset Acquisition [Abstract] | ||||
| Purchase agreement percentage | 100.00% | |||
| Common stock shares | 3,260,870 | 26,043,406 | 23,008,371 | |
| Market value | $ 1.01 | |||
| Common stock shares | $ 1,000,000 | |||
| Exercise price per share | $ 1.88 | |||
| Common stock period | 5 years | |||
| Aggregate fair value | $ 400,000 | |||
| Expenses incurred | $ 311,000 | |||
| Acquired interest rate | 100.00% | |||
| Asset acquisition description | (i) an aggregate of 2,700,000 shares of Common Stock, (ii) an aggregate of 1,000,000 warrants to purchase shares of Common Stock at an exercise price of $1.88 per share, which may be exercised on a cashless basis, for a period of five years commencing on the date of issuance, (iii) a cash payment in the amount of $1,050,000, (iv) the right to certain milestone payments in an amount up to $5,000,000, and (v) the right to contingent earn-out payments ranging from 3% to 5% of net sales of the drug depending on the amount of such net sales in the applicable measurement period. | |||
| Restrictions agreements | 1,350,000 | |||
| Additional shares of common stock | 112,500 |
| X | ||||||||||
- Definition Asset acquisition description. No definition available.
|
| X | ||||||||||
- Definition Company acquired. No definition available.
|
| X | ||||||||||
- Definition The market value. No definition available.
|
| X | ||||||||||
- Definition The percentage of purchase agreement. No definition available.
|
| X | ||||||||||
- Definition Restrictions agreements. No definition available.
|
| X | ||||||||||
- Definition The aggregate fair value of additional assets that would be required to be posted as collateral for derivative instruments with credit-risk-related contingent features if the credit-risk-related contingent features were triggered at the end of the reporting period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Exercise price per share or per unit of warrants or rights outstanding. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Discount on common shares, or any unamortized balance thereof, shown separately as a deduction from the applicable account(s) as circumstances require. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of shares of common stock issued as dividends during the period. Excludes stock splits. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. No definition available.
|
| X | ||||||||||
- Definition Amount of expense classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|